{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:46Z","timestamp":1787239966255,"version":"build-2736575974"},"reference-count":38,"publisher":"The Korean Association for the Study of the Liver","issue":"3","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"name":"Bristol-Myers Squibb"},{"DOI":"10.13039\/501100008130","name":"Pusan National University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["Clin Mol Hepatol"],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:p>Background\/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM\/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM\/LdT+ADV.Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU\/mL after at least 24 weeks of treatment with LAM\/LdT+ADV for LAM-resistant HBV. Patients were randomized to receive a new treatment (ETV+TDF, n=45) or maintained on the same treatment (LAM\/LdT+ADV, n=46) for 48 weeks. Patients with baseline ADV resistance were excluded.Results: Compared to LAM\/LdT+ADV group, ETV+TDF group had more patients with a virologic response (42\/45 [93.33%] vs. 3\/46 [6.52%], &lt;i&gt;P&lt;\/i&gt;&lt;0.001) and had a greater mean reduction in serum HBV DNA level from baseline (-4.16 vs. -0.37 log10 IU\/mL, &lt;i&gt;P&lt;\/i&gt;&lt;0.001). Multivariate analysis indicated that high baseline HBV DNA level (&lt;i&gt;P&lt;\/i&gt;=0.005) and LAM\/LdT+ADV maintenance therapy (&lt;i&gt;P&lt;\/i&gt;=0.001) were negatively associated with virologic response. At week 48, additional ADV- or ETV-associated mutations were cleared in ETV+TDF group, but such mutations were present in 4.3% of patients in LAM\/LdT+ADV group (P=0.106). The two groups had similar rates of adverse events.Conclusions: ETV+TDF combination treatment led to a significantly higher rate of virologic response compared to LAM\/LdT+ADV combination treatment in patients with LAM-resistant HBV who had suboptimal responses to LAM\/LdT+ADV regardless of HBV genotypic resistance profile (NCT01597934).<\/jats:p>","DOI":"10.3350\/cmh.2019.0044n","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:59:32Z","timestamp":1590627572000},"page":"352-363","update-policy":"https:\/\/doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Entecavir+tenofovir vs. lamivudine\/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response"],"prefix":"10.3350","volume":"26","author":[{"given":"Hyun Young","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Young","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1902","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"ref3","first-page":"227","volume-title":"EASL clinical practice guidelines: management of chronic hepatitis B","year":"2009"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9080-3"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.09.062"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.026"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20760"},{"key":"ref9","first-page":"1295","volume-title":"Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease","author":"Yuen","year":"2007"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20110"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.018"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21534"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.051"},{"key":"ref15","first-page":"41","volume-title":"Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population","author":"Fung","year":"2007"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.01.007"},{"key":"ref17","first-page":"557","volume-title":"Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B","author":"Santantonio","year":"2009"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1914"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.018"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.223206"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23145"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23246"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.3.242"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1702"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00338-12"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.079"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20939"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.055"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22323"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i47.6996"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2014.8.1.64"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308353"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308435"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2017.0003"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2018.0106"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2017.0045"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.011"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2019-0044n.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2019.0044n","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2019-0044n.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T04:36:27Z","timestamp":1594355787000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2019.0044n"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2019.0044n","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"2019-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-28","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}